tiprankstipranks
Natural Alternatives International (NAII)
NASDAQ:NAII

Natural Alternatives International (NAII) AI Stock Analysis

85 Followers

Top Page

NAII

Natural Alternatives International

(NASDAQ:NAII)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
$3.00
▼(-4.76% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance—deep losses, low margins, and increased leverage—despite a strong revenue rebound and still-positive operating and free cash flow. Technicals remain mixed-to-weak (below key longer-term moving averages with negative MACD), and valuation is penalized by negative earnings (negative P/E) with no dividend yield provided.
Positive Factors
Strong revenue rebound
TTM revenue growth (+54.9%) reflects a durable rebound in demand and expanding sales scale. NAII's mix of contract manufacturing and branded channels supports higher capacity utilization and deeper customer relationships, bolstering revenue stability over multiple quarters.
Negative Factors
Low margins and net losses
Low gross margins (~8.1%) and a negative net margin (~-14.4%) indicate structural profitability pressure. Thin margins limit reinvestment capacity and resilience to cost inflation; achieving durable profitability will likely require material price/mix improvements or cost structure changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue rebound
TTM revenue growth (+54.9%) reflects a durable rebound in demand and expanding sales scale. NAII's mix of contract manufacturing and branded channels supports higher capacity utilization and deeper customer relationships, bolstering revenue stability over multiple quarters.
Read all positive factors

Natural Alternatives International (NAII) vs. SPDR S&P 500 ETF (SPY)

Natural Alternatives International Business Overview & Revenue Model

Company Description
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Asia, and internationally. The company operates in two segments, Private-Label Contract Manufacturi...
How the Company Makes Money
NAII generates revenue primarily from two sources. (1) Contract Manufacturing: NAII earns money by providing manufacturing services to other companies (brands and marketers of nutritional supplements). Revenue in this segment typically comes from ...

Natural Alternatives International Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how much each business segment contributes to overall sales, indicating which areas drive growth and where diversification or expansion opportunities may exist.
Chart InsightsNatural Alternatives International's Private Label Contract Manufacturing segment is showing signs of recovery after a dip in 2023, with a steady upward trend into 2025. This suggests a potential stabilization and renewed demand. Meanwhile, the Patent and Trademark Licensing segment remains volatile, with recent declines indicating potential challenges in monetizing intellectual property. Investors should watch for strategic shifts or new partnerships that could stabilize licensing revenues and capitalize on manufacturing momentum.
Data provided by:The Fly

Natural Alternatives International Financial Statement Overview

Summary
Revenue rebounded strongly (+54.9% TTM), but profitability has deteriorated to deep losses (net margin ~-14.4%) with weak gross margin (~8.1%) and poor earnings stability versus prior profitable years. Leverage has risen meaningfully (debt ~0.86x equity), offset partly by positive operating cash flow (~$6.4M) and positive free cash flow (~$1.7M) that indicate some underlying cash-generating capacity despite accounting losses.
Income Statement
22
Negative
Balance Sheet
45
Neutral
Cash Flow
52
Neutral
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue134.47M129.86M113.80M154.01M170.97M178.52M
Gross Profit11.56M9.29M6.87M18.16M30.51M30.44M
EBITDA-364.00K-2.70M-4.46M11.09M20.66M16.58M
Net Income-12.25M-13.57M-7.22M2.52M10.71M10.77M
Balance Sheet
Total Assets153.30M151.94M162.34M134.15M146.00M120.28M
Cash, Cash Equivalents and Short-Term Investments3.75M12.32M11.98M13.60M21.83M32.13M
Total Debt106.51M59.03M60.29M30.93M31.84M16.48M
Total Liabilities86.25M83.51M79.75M45.38M57.48M40.20M
Stockholders Equity67.05M68.43M82.59M88.77M88.52M80.08M
Cash Flow
Free Cash Flow-5.24M2.32M-4.51M-6.50M-14.62M15.70M
Operating Cash Flow-1.01M5.93M-1.50M7.02M11.87M20.81M
Investing Cash Flow-4.22M-3.61M-3.02M-13.47M-26.46M-5.04M
Financing Cash Flow326.00K-1.97M2.89M-1.78M4.29M-14.11M

Natural Alternatives International Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.15
Price Trends
50DMA
2.99
Negative
100DMA
3.29
Negative
200DMA
3.28
Negative
Market Momentum
MACD
-0.07
Negative
RSI
44.48
Neutral
STOCH
15.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAII, the sentiment is Negative. The current price of 3.15 is above the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.99, and below the 200-day MA of 3.28, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 44.48 is Neutral, neither overbought nor oversold. The STOCH value of 15.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAII.

Natural Alternatives International Risk Analysis

Natural Alternatives International disclosed 22 risk factors in its most recent earnings report. Natural Alternatives International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Natural Alternatives International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
$93.25M23.1815.30%12.44%-20.33%
61
Neutral
$462.55M19.9012.18%6.62%-7.85%
56
Neutral
$52.07M70.5424.97%2.81%16.77%143.30%
53
Neutral
$333.52M33.562.03%5.88%-68.62%
46
Neutral
$17.29M-2.11-17.43%18.19%-35.22%
45
Neutral
$79.82M-0.21-111.73%-10.13%-532.32%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NAII
Natural Alternatives International
2.80
-0.01
-0.36%
NATR
Nature's Sunshine Products
26.42
14.66
124.66%
HAIN
Hain Celestial
0.88
-2.55
-74.43%
USNA
USANA Health
18.07
-7.21
-28.52%
LFVN
LifeVantage
4.07
-10.87
-72.76%
FTLF
FitLife Brands
9.93
-2.09
-17.39%

Natural Alternatives International Corporate Events

Business Operations and StrategyExecutive/Board Changes
Natural Alternatives Reassigns CEO Role to Lead Swiss Operations
Positive
Mar 20, 2026
Natural Alternatives International, Inc. amended Chief Executive Officer Mark A. LeDoux’s employment agreement effective May 1, 2026, cutting his base salary from $475,000 to $255,000 and reducing certain officer benefits. At the same time, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026